Research analysts at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a report released on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
Genocea Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.61.
About Genocea Biosciences
Further Reading
- Five stocks we like better than Genocea Biosciences
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- 3 Best Fintech Stocks for a Portfolio Boost
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.